News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Researchers Create Nanoparticle that Targets Cancer to Optimize MRI Scanning; New Technology Has Potential to Reduce Number of Tissue Biopsies and Pathology Testing

Researchers at Imperial College London report that their new nanoparticles make it possible for cancer to be visible in magnetic resonance imaging

Even as pathologists are working to develop more sensitive and accurate diagnostic tests for cancer, similar efforts are underway in radiology and imaging. In fact, one research team has developed a self-assembling nanoparticle that can adhere to cancer cells, thus making them visible in MRI scans and possibly eliminate the need for invasive tissue biopsies.

Clinical pathologists and medical laboratory managers will be interested in this research, which is being done at Imperial College London (Imperial). Researchers there have developed a self-assembling nanoparticle that targets cancer cells and makes them visible on magnetic resonance imaging (MRI) scans. (more…)

Start-up Company Hopes Its Revolutionary Hand-Held Device May Render Current MRI and Ultrasound Testing Obsolete

Venture capitalists are betting $100 million that an entrepreneur can develop an inexpensive and portable imaging device that can be used by office-based physicians

There’s a serious effort, funded by venture capitalists, to create a compact medical imaging device with the capabilities to disrupt the existing radiology profession. Developers intend to create a more accurate imaging technology that also costs much less than the expensive imaging systems in common use today.

Biomedical entrepreneur Jonathan Rothberg aims to create a new hand-held medical imaging device that can make MRI and ultrasounds significantly cheaper and more efficient, reported Wired magazine. Rothberg is founder of the Butterfly Network, Inc. 

Rothberg’s goal is to make it possible for office-based physicians to use a point-of-care imaging tool that costs just a couple hundred dollars. It might also help patients in poor regions of the world gain access to imaging tests and better healthcare. (more…)

Public Hospital in Phoenix Slashes Patient Self-Pay Prices by 50% to Increase Hospital Price Transparency

Maricopa Integrated Health System reports that price transparency pays off by reducing uncompensated care and increasing business

Arizona has a new law that requires hospitals, medical laboratories, diagnostic imaging facilities, ambulatory surgery centers, and urgent-care centers to publish the prices they charge self-pay and uninsured patients for the 50 most common inpatient and outpatient services. The law took effect on January 1, 2014.

News accounts report that just one hospital took steps to publish its prices earlier this year. Pathologists and clinical laboratory managers will find the experience of Maricopa Integrated Health System to be instructive, as hospital administrators there publicly state that this was the right thing to do for patients in their community. (more…)

GE Healthcare Pays $587 Million to Purchase Clarient, the Specialty Pathology and Cancer Testing Firm

GE’s Acquisition Considered A Sign Of More Deals To Come In The Clinical Laboratory Industry

Here’s more confirmation that anatomic pathology continues to be a big target on the radar screen of big healthcare corporations and Wall Street investors. Today, GE Healthcare, a unit of General Electric Company (NYSE: GE), disclosed it will pay $587 million to acquire Clarient, Inc. (NASDAQ: CLRT), the medical testing laboratory.

For pathologists and clinical laboratory managers, this is further confirmation that GE—one of the world’s major players in molecular imagin and radiology—intends to combine molecular diagnostic technologies used in anatomic pathology with its molecular imaging technologies used in radiology. In the press release about the acquisition, GE wrote that the addition of Clairent would help it create “new integrated tools for the diagnosis and characterization of cancer.”

(more…)

;